Immunotherapy Treatment for Triple Negative Breast Cancer

Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of breast cancer and has dismal prognosis. Local recurrence rate after standard therapy in the early breast cancer setting can be upwards to 72% in 5 years, and in the metastatic setting, the 5-year overall survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Elizabeth R., Park, Tristen, Saridakis, Angeleke, Golshan, Mehra, Greenup, Rachel A., Ahuja, Nita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401402/
https://www.ncbi.nlm.nih.gov/pubmed/34451860
http://dx.doi.org/10.3390/ph14080763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401402/
https://www.ncbi.nlm.nih.gov/pubmed/34451860
http://dx.doi.org/10.3390/ph14080763

Ejemplares similares